Key Facts
| Item | Detail |
|---|---|
| Instrument | EU Twinning (institution-building tool for accession candidates) |
| Objective | Establish a State Control Body for medicines, medical devices, IVDs, cosmetics, blood & narcotics supervision |
| Call for proposals | Open to EU member states until 23 July 2025 |
| Project length | 18 months |
| Partner country announcement | Target date 8 August 2025 |
| Funding stream | Ukraine Facility 2024 (EU technical-assistance window) |
Why It Matters
-
Regulatory convergence: The new authority will be modelled on EMA and leading EU national agencies, harmonising GMP/GDP inspections, pharmacovigilance, import licensing and market surveillance.
-
Market confidence: Clear, EU-aligned oversight is a prerequisite for international pharma and med-tech firms considering local manufacturing, clinical trials or distribution hubs in Ukraine.
-
Accession pathway: This is the first Twinning project launched in the Ukrainian health sector—an early milestone in meeting Chapter 28 (Consumer & Health Protection) of the acquis.
What the Project Covers
-
Institutional architecture – legal set-up, governance model, financing.
-
Capacity building – EU experts will train Ukrainian inspectors and evaluators on:
-
GMP/GDP facility audits
-
Pharmacovigilance & vigilance for devices
-
Licensing of importers & wholesale distributors
-
Cosmetics and narcotics market surveillance
-
-
Digital tools & data exchange – alignment with EudraGMDP, EudraVigilance and future European Medical Device databases.
-
Public-health communications – risk-based alerts and transparency standards.
Next Steps
-
EU member states assemble consortia and file bids by 23 July.
-
European Commission evaluates proposals and names the lead partner country in early August.
-
Kick-off expected in Q4-2025, once administrative agreements and detailed work plans are signed.
“Creating a modern, independent regulator is essential for ensuring that Ukrainian patients receive safe, effective and high-quality products while giving industry a predictable, EU-compatible environment,” Ukraine’s Ministry of Health stated.
Bottom line for life-science stakeholders: A unified regulator built to EU specs will cut duplication, speed approvals and open a transparent path for cross-border investment in Ukraine’s pharmaceutical, biotech and med-tech sectors.
